F2-ISoP Levels in CSF a Potential Biomarker of Therapy-Related Cognitive Outcomes in Children With ALL
Researchers sought to determine if F2-ISoP levels could be a biomarker for cognitive dysfunction in children with ALL.
Diagnosis & Disease Information
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Blinatumomab Improved Survival for Patients With B-Cell ALL, but Not Significantly
Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.
Leukemia: Fact Sheet for Patients
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Anti-CD19 CAR T-Cell Therapy Effective in Relapsed/Refractory B-Cell Acute Lymphocytic Leukemia
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
[Blood and Lymphatic Cancer: Targets and Therapy] Although this retrospective analysis determined that ibrutinib was not associated with higher mortality in older patients with CLL, it did find greater intolerance with an increased number of early deaths in elderly patients treated with ibrutinib.
Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL
Patients with B-cell ALL who are treated with CAR T-cell therapy and allo-HSCT may have better outcomes than those treated only with CAR T-cell therapy.
Managing Pegasparaginase Toxicities in Adults With Acute Lymphoblastic Leukemia
Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...